Last reviewed · How we verify
Perfluorohexyloctane ophthalmic solution
Perfluorohexyloctane ophthalmic solution, marketed by Bausch & Lomb Incorporated, holds a unique position in the ophthalmic market with its key composition patent expiring in 2028. The drug's primary strength lies in its distinct mechanism of action, which differentiates it from existing treatments. The primary risk to consider is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Perfluorohexyloctane ophthalmic solution |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease (PHASE4)
- A Study to Evaluate the Safety and Effectiveness of Perfluorohexyloctane Eye Drops on Treatment of Dry Eye Disease (DED) Related to Meibomian Gland Dysfunction (MGD)
- A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear (PHASE4)
- A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease (PHASE4)
- Treating Lid Wiper Epitheliopathy (PHASE4)
- A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months. (PHASE4)
- Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study) (PHASE3)
- Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |